Race Receives Cardioprotection Ethics Trial Approval
Latest announcements
Announcement summary
Race Receives Cardioprotection Ethics Trial Approval
Race Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial:
- Human ethics approval received for the initial observational stage of a plannedinterventional Phase 1/2b cardioprotection clinical program using Zantrene
- Research institutional governance submission is expected soon and will enable enrolment of the first study patient
- This observation trial is the first step in advancing the cardioprotection opportunity for Zantrene in the clinic.
Ask a question
Your question will be sent privately to Race Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Race Oncology a question about this announcement.